Not yet independently audited
This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.
Lung adenocarcinoma — clinical trials landscape¶
TL;DR — The lung-adenocarcinoma trial landscape is not one pipeline: it is a portfolio of genotype-specific inhibitor sequences, first-line combinations, perioperative strategies, antibody–drug conjugates, ctDNA/MRD-guided studies, CNS studies, and resistance baskets. Live ClinicalTrials.gov API queries on 2026-08-29 returned 490 recruiting/not-yet-recruiting/active-not-recruiting records explicitly indexed to “lung adenocarcinoma” and 2,429 under “non-small cell lung cancer”; these counts overlap and include trials not specific to this histology. Current pivots include first-line KRAS G12C combinations, subcutaneous versus intravenous amivantamab, repotrectinib against crizotinib, mutation-selective HER2 TKIs, and postoperative MRD intervention. Every NCT identifier and its status, phase, and enrollment field were re-fetched through the ClinicalTrials.gov v2 API during the 2026-08-29 audit; status remains a dated snapshot, not a permanent fact. Trial interpretation should separate randomized evidence, single-arm response cohorts, platform-screening denominators, and expansion cohorts.
Registry snapshot and method¶
Queries used ClinicalTrials.gov API v2 on 2026-08-29. “Active” below combines RECRUITING, NOT_YET_RECRUITING, and ACTIVE_NOT_RECRUITING.
| Registry condition query | Active | Completed | Interpretation |
|---|---|---|---|
| Non-Small Cell Lung Cancer | 2,429 | 3,247 | Broad mixed-histology universe; includes prevention, procedures, supportive care, and observational studies |
| Lung Adenocarcinoma | 490 | 578 | More specific but indexing-dependent; not a complete molecular-trial count |
Counts should not be added because the sets overlap. Status and enrollment fields are sponsor-submitted registry data, not proof of recruitment at a particular site.
Registry recheck, 2026-10-16¶
All 42 NCT identifiers cited in this condition were re-fetched through the ClinicalTrials.gov API v2 on 2026-10-16. The disease-level counts were essentially unchanged: NSCLC 2,437 active / 3,265 completed, lung adenocarcinoma 497 active / 584 completed.
| Change type | Records |
|---|---|
| Status change | NCT06524427 (RAVAR): Recruiting → Active, not recruiting |
| Results newly posted to the registry since 2026-08-28 | None |
| Results published in journals but not posted to the registry | NCT05601973 (AMAZE-lung, PMID 42833236); NCT03769103 (LUOSICNS, within STARLET, PMID 41534788) |
| Primary completion date passed, no results posted | NCT05132075 (2026-09-03); NCT04819100 (2026-01-12); NCT05650879 (2026-07); NCT03175224 (2026-03-30, still listed Recruiting) |
| Probably stale: completion date passed, record not updated since 2023–2025 | NCT06156527 (last update 2023-12, primary completion 2026-09-05, still Recruiting); NCT06854939 and NCT06682884 (still Not yet recruiting after their primary completion dates); NCT05965024 (last update 2024-02) |
Randomized trials newly cited elsewhere in this condition were checked live on the same date: NCT04214262 (S1914; active, not recruiting; results posted), NCT04695925 (EGFR/TP53 osimertinib ± chemotherapy; active, not recruiting), NCT06396065 (HARMONi; active, not recruiting), and NCT03497767 (OUTRUN; completed). ChiCTR2000040590 (ADVANCE) is not on ClinicalTrials.gov. The WHO ICTRP record served on 2026-10-16 still listed it as "Pending", although the trial was stopped early and published (PMID 42764281). The ChiCTR site itself returned HTTP 405.
Registry recheck, 2026-10-23¶
The live API v2 sweep resolved 50 distinct NCT IDs present in this condition's Markdown, including IDs in the literature and question layers. The preceding manifest stores comparable status/results fields for 42; its seven newly cited IDs are only a list, and eight IDs in today's complete Markdown set lack a saved field-level baseline. This corrects the earlier claim that 42 represented every cited ID.
| Check | Finding on 2026-10-23 |
|---|---|
| Status and results-availability comparison | No overall-status change or newly posted results among the 42 records with saved comparison fields |
| Results first posted within the requested publication window | NCT04214262 (S1914): 2026-10-06. Already noted as having posted results in the prior sweep; this is not a newly detected posting since 2026-10-16 |
| Updated registry record | NCT06162221 (RAS(ON) platform): last update posted 2026-10-19, formerly 2026-06-30; still Recruiting, no results posted; estimated primary completion 2027-06. An update date alone does not identify which protocol fields changed |
| Prior priority follow-ups | NCT05132075 and NCT04819100 remain Active, not recruiting, without posted results |
| Other elapsed primary-completion dates | NCT05650879 and NCT03175224 still have no posted results; retain the dated follow-up rather than infer study outcomes |
| Remaining eight IDs | Current snapshots obtained; no claim about interval changes without a stored baseline |
WHO ICTRP was requested for the previously cited ADVANCE registration but returned HTTP 502. A direct ChiCTR query served an anti-bot script, while ISRCTN search required JavaScript/cookies and the attempted API route returned HTTP 404. None yielded a usable current non-US trial record. The prior WHO status is therefore not refreshed. No disease-level trial counts were recalculated in this sweep.
Registry recheck, 2026-10-30¶
All 50 previously tracked NCT IDs resolved live through ClinicalTrials.gov API v2. Compared with the 2026-10-23 field-level snapshots, overall status and results-first-posted dates were unchanged. Disease-level counts on this date: NSCLC 2,463 active / 3,274 completed; lung adenocarcinoma 500 active / 586 completed.
| Check | Finding on 2026-10-30 |
|---|---|
| Status and results-availability comparison | No overall-status change or newly posted results among the 50 tracked IDs |
| Last-update-posted after 2026-10-23 | NCT04214262 (S1914) 2026-10-27; NCT04538664 (PAPILLON) 2026-10-29. Both already had posted results; an update date alone does not identify which protocol fields changed |
| Prior priority follow-ups | NCT05132075, NCT04819100, NCT05650879 remain Active, not recruiting, without posted results; NCT03175224 remains Recruiting without posted results |
| Newly cited trials this sweep | NCT06497556 (Krascendo 1, Active not recruiting, n=338 actual, no results posted); NCT06382116 (PANKU-Lung01); NCT06671379 (HERON-Lung01); NCT06110663 (dalmelitinib, UNKNOWN, last update 2023-11-01); NCT04325763 (R-ALPS, UNKNOWN, last update 2022-03-31); NCT04547504 (PERSEE); NCT03924869 (KEYNOTE-867, Terminated, results first posted 2025-05-11); NCT05184712 (HARMONi-A); NCT05341583 (ELEVATE) |
| Non-US registries | WHO ICTRP served ChiCTR2000040590 (HTTP 200); the record still lists recruitment as Pending and was last refreshed 15 March 2021. Direct ChiCTR and CTRI were not usable. ISRCTN API returned HTTP 200 with a large payload but no trial-level ADVANCE match was extracted. SciELO/LILACS and CENTRAL were not searched (HTTP 403 / blocked) |
How to read the portfolio¶
| Design | What it can establish | Common trap |
|---|---|---|
| Randomized phase III | Comparative efficacy/safety under protocol | Crossover and subsequent therapy can dilute OS |
| Single-arm registrational cohort | Response rate and duration in rare genotype | Historical controls and selected patients |
| Basket trial | Activity across rare molecular states | Mixing tumor types and variants |
| Platform trial | Efficient molecular screening and cohort replacement | Counting screened patients as treated evidence |
| MRD-guided trial | Clinical utility of acting on ctDNA | Treating prognostic validation as intervention proof |
| Real-world cohort | Generalizability and rare safety | Confounding by access and treatment selection |
EGFR portfolio¶
| NCT | Study | Phase/status on 2026-08-29 | Design question |
|---|---|---|---|
| NCT06376084 | Osimertinib with chemotherapy first line | Active, not recruiting; n=532 | Confirms/intends regional evidence for intensification |
| NCT03769103 | Osimertinib + SRS vs osimertinib alone for brain metastases (LUOSICNS) | Active, not recruiting; phase 2; n=40 | Whether upfront local CNS therapy adds benefit. Results published in the pooled STARLET analysis with OUTRUN (NCT03497767): no significant 12-month intracranial-PFS gain (PMID 41534788) |
| NCT05256290 | Silevertinib/BDTX-1535 in EGFR-mutant NSCLC/GBM | Active, not recruiting; phase 1/2; estimated n=200 | Mutation-selective next-generation EGFR inhibition |
| NCT04486833 | Quaratusugene ozeplasmid + osimertinib after osimertinib progression | Recruiting; phase 1/2; estimated n=158 | Gene-therapy combination and resistance |
| NCT06156527 | Lazertinib ± bevacizumab in EGFR-positive smokers | Recruiting; phase 2; n=120 | Angiogenesis intensification in a selected phenotype |
| NCT05801029 | Osimertinib + amivantamab in common EGFR mutations | Active, not recruiting; phase 2; n=60 | Dual EGFR/MET blockade without chemotherapy |
| NCT05601973 | Amivantamab-lazertinib-bevacizumab after third-generation TKI (AMAZE-lung) | Active, not recruiting; phase 2; n=60 | Triple targeted/antiangiogenic resistance strategy. Primary analysis published: 12-week ORR 33% (PMID 42833236); no results posted to the registry as of 2026-10-16 |
| NCT06784791 | Preoperative amivantamab ± platinum-pemetrexed | Recruiting; phase 2; n=20 | Neoadjuvant EGFR-directed therapy and pathologic response |
| NCT04538664 | PAPILLON: amivantamab + chemotherapy in exon-20 insertion | Active, not recruiting; phase 3; n=308 | Completed pivotal first-line comparison; ongoing follow-up |
| NCT05388669 | Subcutaneous vs IV amivantamab with lazertinib | Active, not recruiting; phase 3; n=418 | Administration, reactions, PK, and efficacy |
| NCT06382116 | PANKU-Lung01: izalontamab brengitecan vs platinum-pemetrexed after third-generation EGFR TKI | Active, not recruiting; phase 3; actual n=432 | EGFR×HER3 ADC vs chemotherapy; primary report published (PMID 42933461); no results posted |
| NCT06671379 | HERON-Lung01: ruzaltatug rezetecan vs platinum-pemetrexed after EGFR TKI | Active, not recruiting; phase 3; actual n=498 | HER3 ADC vs chemotherapy; interim PFS report published (PMID 42933457); no results posted |
| NCT05184712 | HARMONi-A: ivonescimab + chemo vs chemo after EGFR TKI (China) | Active, not recruiting; phase 3; actual n=322 | China-only OS-positive ivonescimab trial (PMID 42307937); distinct from global HARMONi NCT06396065 |
The published EGFR evidence path—from IPASS through FLAURA, ADAURA, and PAPILLON—shows why genotype and line of therapy must be explicit (PMIDs: 19692680, 29151359, 32955177, 37870976).
ALK, ROS1, and RET portfolio¶
| NCT | Driver/study | Status/phase | Question |
|---|---|---|---|
| NCT06682884 | Neoadjuvant lorlatinib in stage IB–IIIB ALK-positive NSCLC | Not yet recruiting; phase 2; n=25 | Pathologic response and perioperative feasibility |
| NCT07374614 | Iruplinalkib after lorlatinib in ALK-positive adenocarcinoma | Recruiting; n=20 | Post-lorlatinib sequencing |
| NCT06007937 | Lorlatinib + ramucirumab | Active, not recruiting; phase 1/2; actual n=9 | Antiangiogenic combination feasibility |
| NCT06140836 | TRIDENT-3: repotrectinib vs crizotinib | Active, not recruiting; phase 3; n=190 | Randomized first-line ROS1 comparison |
| NCT03093116 | TRIDENT-1 repotrectinib basket | Recruiting; phase 1/2; estimated n=500 | ROS1/NTRK activity and resistance cohorts |
| NCT06315010 | Repotrectinib in active ROS1-positive brain metastases | Recruiting; phase 2; n=20 | Prospective CNS activity |
| NCT06552234 | Repotrectinib in frail/older ROS1-positive NSCLC | Recruiting; phase 2; n=30 | Generalizability beyond pivotal fitness |
| NCT04268550 | Lung-MAP RET-fusion targeted treatment | Active, not recruiting; phase 2; n=124 | Cooperative-group RET pathway |
| NCT04819100 | Selpercatinib after surgery/radiation | Active, not recruiting; phase 3; n=152 | Adjuvant RET inhibition |
| NCT03157128 | LIBRETTO-001 | Active, not recruiting; phase 1; n=857 | Long-term and rare-cohort selective RET evidence |
Published anchors are ALEX/CROWN for ALK, entrectinib/TRIDENT-1 for ROS1, and LIBRETTO-431 for RET (PMIDs: 28586279, 33207094, 31838015, 38197815, 37870973).
KRAS and RAS portfolio¶
| NCT | Study | Status/phase | Why it matters |
|---|---|---|---|
| NCT06497556 | Krascendo 1: divarasib vs sotorasib or adagrasib | Active, not recruiting; phase 3; actual n=338 | Later-line next-generation vs first-generation G12C; primary report published (PMID 42929675); no results posted to the registry |
| NCT06793215 | Divarasib + pembrolizumab vs pembrolizumab-platinum-pemetrexed | Recruiting; phase 3; n=600 | Moves G12C targeting into first line with direct standard comparator |
| NCT03600883 | CodeBreaK 100 | Completed; phase 1/2; actual n=713 | Foundational sotorasib dose-expansion platform |
| NCT06162221 | RAS(ON) inhibitors in RAS-mutant NSCLC | Recruiting; phase 1/2; estimated n=616 | Beyond GDP-state G12C inhibition and beyond G12C |
| NCT05132075 | JDQ443 vs docetaxel | Active, not recruiting; phase 3; n=95 | Comparative later-line G12C evidence |
| NCT06917079 | BBO-11818 in KRAS-mutant cancers | Recruiting; phase 1; n=665 | Broad KRAS-mutant early development |
| NCT07339839 | Glecirasib + ivonescimab first line | Not yet recruiting; phase 1/2; estimated n=42 | KRAS plus immune/VEGF-bispecific strategy |
| NCT07198841 | IBI351 + cetuximab in untreated G12C NSCLC | Recruiting; phase 2; n=48 | Feedback-blockade strategy |
CodeBreaK 200 and KRYSTAL-12 show that randomized later-line comparisons are feasible; PFS benefit must be interpreted alongside toxicity, crossover, OS, and patient-reported outcomes (PMIDs: 36764316, 40783289, 39303400). Krascendo 1 now supplies an OS-positive later-line comparison of divarasib against first-generation G12C inhibitors (PMID 42929675). First-line G12C combinations remain investigational (NCT06793215).
MET, HER2, and rare-driver portfolio¶
| NCT | Driver/study | Status/phase | Question |
|---|---|---|---|
| NCT06031688 | Lung-MAP MET exon-14 cohort | Recruiting; phase 2; n=56 | Cooperative-group targeted pathway |
| NCT03175224 | APL-101 in MET-altered solid tumors/NSCLC | Recruiting; phase 2; n=497 | Next MET inhibitor and resistance |
| NCT06110663 | Dalmelitinib + aumolertinib vs chemotherapy after EGFR-TKI, MET-amplified | UNKNOWN (last update 2023-11-01); phase 3; estimated n=314 | Dual EGFR/MET vs chemotherapy; primary report published (PMID 42928710); no results posted |
| NCT02414139 | GEOMETRY mono-1 capmatinib | Completed; phase 2; n=373 | Pivotal METex14 evidence |
| NCT03944772 | ORCHARD after first-line osimertinib | Active, not recruiting; phase 2; n=247 | Biomarker-matched resistance cohorts including MET |
| NCT05650879 | ELVN-002 in HER2-mutant NSCLC | Active, not recruiting; phase 1; n=198 | HER2-selective TKI |
| NCT05246514 | T-DXd in HER2-mutant NSCLC | Active, not recruiting; phase 2; n=72 | ADC efficacy and ILD characterization |
| NCT06760819 | Sevabertinib in HER2-mutant solid tumors | Recruiting; phase 2; n=111 | Mutation-selective oral therapy |
| NCT07192068 | Zanidatamab in HER2-altered tumors | Recruiting; phase 2; n=105 | Bispecific HER2 targeting across alteration states |
These trials must keep mutation, amplification, overexpression, and exon skipping separate. Published anchors include GEOMETRY/VISION, DESTINY-Lung02, and zongertinib (PMIDs: 32877583, 32469185, 37694347, 40293180).
MRD and perioperative portfolio¶
| NCT | Study | Status/phase | Clinical-utility question |
|---|---|---|---|
| NCT04841811 | APPROACH: MRD-guided maintenance in EGFR-mutant stage III | Active, not recruiting; phase 3; n=192 | Integrates local therapy, TKI, and MRD |
| NCT05822284 | ctDNA-MRD after induction chemo-IO in stage IIIB–C | Not yet recruiting; n=50 | Prognostic monitoring in locally advanced disease |
| NCT05965024 | MRD prediction after resection | Recruiting; n=377 | Sampling schedule and recurrence prediction |
| NCT06854939 | MRD monitoring frequency after curative treatment | Not yet recruiting; n=350 | How often to sample and act |
| NCT06951646 | CR1STAL-Adaptive ctDNA-guided escalation after durable IO response | Recruiting; phase 2; n=70 | Advanced-disease molecular escalation |
| NCT04585490 | Personalized consolidation after chemoradiation/immunotherapy | Recruiting; phase 3; n=48 | Biomarker-directed stage III intensification |
| NCT06524427 | RAVAR robot-assisted vs video-assisted lobectomy | Active, not recruiting as of the 2026-10-06 registry update (was Recruiting on 2026-08-29); estimated n=1,124 | Surgical platform comparison |
| NCT03924869 | KEYNOTE-867: SBRT ± pembrolizumab, unresected stage I–II | Terminated; phase 3; actual n=448; results first posted 2025-05-11 | Negative EFS; published 2026-10-28 (PMID 42950173) |
| NCT04325763 | R-ALPS: benmelstobart ± anlotinib after CRT | UNKNOWN (last update 2022-03-31); phase 3; estimated n=315 | China-only stage III consolidation; published (PMID 42955021) |
| NCT05341583 | ELEVATE: adjuvant ensartinib vs placebo | Check registry at point of use | Two-year adjuvant ALK TKI after chemotherapy (PMID 42418775) |
| NCT04547504 | PERSEE: pembrolizumab ± chemotherapy, PD-L1 ≥50% | Active, not recruiting; phase 3; actual n=349 | First-line head-to-head; published (PMID 42927854); no results posted |
Observational MRD association is already strong (PMIDs: 28899864, 28445469, 34844976); these studies matter only if they show that acting on ctDNA improves outcomes.
Trial-design failure modes¶
| Failure | Consequence | Better design |
|---|---|---|
| Molecular cohort too broad | Dilutes allele-specific activity | Predefine exact variant and resistance state |
| CNS exclusion | Inflates apparent systemic benefit | Include stable/active CNS cohorts with intracranial endpoints |
| ORR without duration | Short responses appear equivalent | Report duration, PFS, CNS progression, and subsequent therapy |
| Platform denominator hidden | Screen failure and access invisible | Report screened, assigned, treated, and evaluable separately |
| MRD positivity without action comparator | Prognostic result mislabeled utility | Randomize the action triggered by MRD |
| Post-progression crossover ignored | OS interpreted naively | Report treatment switching and estimands |
| Sponsor status treated as site availability | Patients referred to closed sites | Verify site-level recruitment directly |
Open questions¶
- Which first-line KRAS combination improves OS and quality of life without excess immune/hepatic toxicity?
- Can randomized CNS-specific trials establish when radiation can be deferred for driver-positive disease?
- Which MRD intervention improves cure rather than merely advancing relapse detection?
- How should rare-driver trials pool globally while preserving allele, ancestry, and CNS detail?
- Can platform trials report screening attrition and turnaround as co-primary implementation outcomes?
- Which post-targeted-therapy resistance states need tissue rather than plasma for trial assignment?
Related pages¶
- Molecular testing — trial-screening assays.
- Systemic therapy — current standard comparators.
- Biomarkers — MRD and response endpoints.
- Early-stage and perioperative therapy — perioperative designs.
- Open questions — prioritized study-shaped gaps.
References¶
- Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009. PMID 19692680
- Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018. PMID 29151359
- Wu YL, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020. PMID 32955177
- Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023. PMID 37870976
- Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017. PMID 28586279
- Shaw AT, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020. PMID 33207094
- Drilon A, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020. PMID 31838015
- Drilon A, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024. PMID 38197815
- Zhou C, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023. PMID 37870973
- Skoulidis F, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021. PMID 34096690
- de Langen AJ, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023. PMID 36764316
- Barlesi F, et al. Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025. PMID 40783289
- Waterhouse DM, et al. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Lung Cancer. 2024. PMID 39303400
- Wolf J, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020. PMID 32877583
- Paik PK, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020. PMID 32469185
- Goto K, et al. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol. 2023. PMID 37694347
- Heymach JV, et al. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025. PMID 40293180
- Chaudhuri AA, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017. PMID 28899864
- Abbosh C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017. PMID 28445469
- Xia L, et al. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Clin Cancer Res. 2022. PMID 34844976
- Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022. PMID 35403841
- Wakelee H, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023. PMID 37272513
- Heymach JV, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023. PMID 37870974
- Wu YL, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024. PMID 38598794
- Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018. PMID 29398453
- Lee CK, et al. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol. 2026;21(5):103549. PMID 41534788
- Soo RA, et al. Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2026. PMID 42833236
- Bi N, et al. Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation. Signal Transduct Target Ther. 2026;11(1):395. PMID 42764281
- Skoulidis F, et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. N Engl J Med. 2026. PMID 42929675
- Hong S, et al. Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01). Lancet. 2026. PMID 42933461
- Xu CR, et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01). Lancet. 2026. PMID 42933457
- HARMONi-A Study Investigators, Fang W, et al. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. JAMA. 2026;336:306-314. PMID 42307937
- Li Z, et al. Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial. J Clin Oncol. 2026. PMID 42928710
- Jabbour SK, et al. KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID 42950173
- Ji Y, et al. Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial. JAMA Oncol. 2026. PMID 42955021
- Yue D, et al. Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2026;395:151-161. PMID 42418775
- Descourt R, et al. Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). Ann Oncol. 2026. PMID 42927854